March 09, 2018 |
The amyloid-β42/40 (Aβ42/40) ratio should be included as a cerebrospinal fluid (CSF) biomarker for Alzheimer disease (AD) and may be appropriate for use in the clinical diagnostic setting, according to a new study. The findings suggest that analysis of Aβ40 as well as Aβ42 concentrations may provide greater sensitivity and specificity.
Psychiatric Times